Abstract: A method of extracting at least one rhamnolipid compound from a rhamnolipid fermentation mixture, the method comprising the steps of: (a) admixing an inert adsorbing support with a rhamnolipid fermentation mixture; (b) dissolving the mixture in an organic solvent at a temperature higher than 31° C. and at a pressure higher than 73 bars; (c) separating at least one fatty compound; (d) adding a co-solvent to said organic solvent; (e) modifying temperature and/or pressure; (f) separating a first rhamnolipid compound; and (g) separating a second rhamnolipid compound.
Type:
Application
Filed:
February 25, 2016
Publication date:
February 15, 2018
Applicant:
Conopco, Inc., d/b/a UNILEVER
Inventors:
Raymond John MARRIOTT, Paul Simon STEVENSON
Abstract: The invention relates to crystalline forms of 5,6-dichloro-2-(isopropylamino)-1-?-L-ribofuranosyl-1Hbenzimidazole, pharmaceutical compositions comprising the same, processes for preparing the same, and their use in medical therapy.
Type:
Application
Filed:
October 5, 2017
Publication date:
February 15, 2018
Inventors:
Bobby Neal GLOVER, Lian-Feng Huang, Robert Williams Lancaster, Stacey Todd Long, Michele Catherine Rizzolio, Eric Allen Schmitt, Barry Riddle Sickles
Abstract: Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
Type:
Application
Filed:
March 28, 2017
Publication date:
February 15, 2018
Inventors:
Byoung-Kwon Chun, Ganapati Reddy Pamulapati, Suguna Rachakonda, Bruce Ross, Michael Joseph Sofia, Peiyuan Wang, Hai-Ren Zhang
Abstract: Compositions and methods in the field of medicine and chemistry are disclosed. Some of the disclosed embodiments are directed to nucleotide compounds, medicinal compositions, as well as processes for their preparation and methods of their use. In some embodiments, such nucleotide compounds are useful antiviral and antimetabolic agents.
Abstract: Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus and/or Flaviviridae infection with one or more nucleosides, nucleotides and nucleotide analogs.
Type:
Application
Filed:
October 23, 2017
Publication date:
February 15, 2018
Inventors:
Leonid Beigelman, Guangyi Wang, David Bernard Smith, Marija Prhavc, Christian Andreas Jekle, Jerome Deval
Abstract: Provided herein are methods for removal of monomethoxytrityl groups from oligomeric compounds comprising terminally linked monomethoxytrityl protected amino groups. The present methods differ from standard methods for 5?-dimethoxytrityl removal from oligonucleotides in that the present methods are performed at elevated temperatures and higher pH. In certain embodiments, the present methods provide detritylated oligomeric compounds having a reduced percentage of depurination relative to the same detritylated oligomeric compounds prepared using standard methods. In certain embodiments, the present methods provide an increased rate of detritylation compared to standard methods. In certain embodiments, the modification of the final detritylation step results in an improved yield.
Abstract: Method and compositions and kits for isolation, identification, and quantification of miRNAs and other small RNAs, including but not limited to, siRNAs, mRNAs, and snRNAs are disclosed. Methods of diagnosing a disease or its progression are also disclosed.
Type:
Application
Filed:
August 21, 2017
Publication date:
February 15, 2018
Inventors:
Tom XU, Christopher TRINH, Carole BORNARTH, Brian EVANS, Mousumi RATH, Kathy TRAN
Abstract: The present disclosure relates to nanostructures assembled from nucleic acid consisting of a single strand of DNA rationally-designed to self-assemble into a hairpin loop, helical domains, and locking domains.
Type:
Application
Filed:
March 4, 2016
Publication date:
February 15, 2018
Applicant:
President and Fellows of Harvard College
Abstract: The invention relates to a method of isolating an immunoglobulin, comprising the steps of: a) providing a separation matrix comprising at least 15 mg/ml multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support, wherein the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml; b) contacting a liquid sample comprising an immunoglobulin with the separation matrix; c) washing the separation matrix with a washing liquid; d) eluting the immunoglobulin from the separation matrix with an elution liquid; and e) cleaning the separation matrix with a cleaning liquid comprising at least 0.5 M NaOH.
Type:
Application
Filed:
October 31, 2017
Publication date:
February 15, 2018
Inventors:
Annika Forss, Mats Ander, Tomas Bjorkman, Hans Blom, Jesper Hansson, Gustav Rodrigo
Abstract: This invention relates to novel 3-amido-4-oxo-5-phenoxypentanoic acids, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a caspase protease inhibitor.
Abstract: Analogs of largazole are described herein. Methods of treating cancer and blood disorders using largazole and largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.
Type:
Application
Filed:
March 3, 2016
Publication date:
February 15, 2018
Inventors:
Robert M. Williams, James E. Bradner, Dane Clausen, Olaf G. Wiest, Tenaya L. Newkirk, Albert A. Bowers, Jennifer Marie Guerra
Abstract: The invention relates to the synthesis of boronic ester and acid compounds. More particularly, the invention provides improved synthetic processes for the large-scale production of boronic ester and acid compounds, including the peptide boronic acid proteasome inhibitor bortezomib.
Abstract: The present technology provides methods of generating the peptides, and pharmaceutically acceptable salts of the peptides and intermediates thereof. In some embodiments, the peptide is D-Arg-2?6?-Dmt-Lys-Phe-NH2.
Abstract: Provided herein are charge complementary peptides that can be optionally coupled to a cargo polypeptide that are capable of self-assembling under stimulating conditions. The charge complementary peptides can be capable of forming supramolecular structures. Also provided herein are methods of using the charge complementary peptides provided herein.
Abstract: Beta-hairpin peptidomimetics of the general formula (I), cyclo[P1-P2-P3-P4-P5-P6-P7-P8-P9-P10-P11-P12-T1-T2], and pharmaceutically acceptable salts thereof, with P1 to P12, T1 and T2 being elements as defined in the description and the claims, have Gram-negative antimicrobial activity to e.g. inhibit the growth or to kill microorganisms such as Klebsiella pneumoniae and/or Acinetobacter baumannii and/or Escherichia coli. They can be used as medicaments to treat or prevent infections or as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.
Type:
Application
Filed:
October 23, 2017
Publication date:
February 15, 2018
Applicant:
POLYPHOR AG
Inventors:
Daniel OBRECHT, Anatol LUTHER, Francesca BERNARDINI, Peter ZBINDEN
Abstract: A polysaccharide derivative has a partial structure represented by Formula (1) below. It is preferable that at least one of the amino acids that constitute X2 in Formula (1) below is a basic amino acid. (In the formula, X1 represents a residue obtained by removing the terminal amino group and the terminal carboxyl group from a neutral amino acid or an ?-aminoalkanoic acid, X2 represents a residue obtained by removing the terminal amino group and the terminal carboxyl group from a membrane-permeable peptide, X3 represents a hydroxyl group, an amino group, an alkoxyl group having 1 to 4 carbon atoms, or a benzyloxy group, a represents a number of 0 or 1, and b represents a number of from 0 to 50.
Type:
Application
Filed:
February 23, 2016
Publication date:
February 15, 2018
Inventors:
Shinji SAKUMA, Kohta MOHRI, Ken-ichiro HIWATARI, Kyohei OCHIAI
Abstract: Spin-labeled ice binding compounds (IBCs) including ice binding proteins (IBPs) or antifreeze proteins (AFPs) and their analogs may carry paramagnetic centers for dynamic nuclear polarization (DNP), for enhancing nuclear magnetic resonance (NMR) signal intensities. Use of spin-labeled IBCs to perform DNP exploits the IBCs' ability to homogeneously distribute the paramagnetic centers in frozen water solution at low temperature, leading to high DNP efficiency. Other advantages of using spin-labeled IBCs include cryo-protecting biological samples; cryo-preserving relative positions and orientations of the spin labeling groups; selecting positions and orientations of spin labeling groups with freedom and without technical barriers to making multiple spin labels in an IBC; and enabling use of a solvent that is primarily water for DNP at low temperatures in view of the potentially high water solubilities of spin-labeled IBCs.
Abstract: Nucleic acid molecules encoding monomeric near-infrared fluorescent proteins, variants and derivatives thereof are provided, as well as proteins and peptides encoded by these nucleic acids. Also provided are proteins that are substantially similar to, or derivatives, homologues, or mutants of, the above-referenced specific proteins. Also provided are fragments of the nucleic acids and the peptides encoded thereby, specifically split fluorescent proteins. In addition, host-cells, stable cell lines and transgenic organisms comprising above-referenced nucleic acid molecules are provided. The invention also refers to methods of making and using monomeric fluorescent proteins derived from bacterial phytochromes. The subject protein and nucleic acid compositions find use in a variety of different applications and methods, particularly for labeling of biomolecules, cells or cell organelles, and for detecting protein-protein interactions. Finally, kits for use in such methods and applications are provided.
Type:
Application
Filed:
April 26, 2017
Publication date:
February 15, 2018
Applicant:
Albert Einstein College of Medicine, Inc.
Inventors:
Vladislav V. Verkhusha, Daria M. Shcherbakova, Mikhail Baloban
Abstract: The present disclosure provides compositions comprising recombinant bacterial spores. The present disclosure is also directed to vaccine based compositions, which include recombinant bacterial spores that express CTB and a peanut protein(s) on their surfaces. This disclosure also provides methods for administering these compositions as a treatment or prevention of peanut allergy.
Type:
Application
Filed:
February 17, 2017
Publication date:
February 15, 2018
Inventors:
Xiu-Min LI, Zhenwen Zhou, Zhigang LIU, Ying SONG
Abstract: Methods and compositions are provided concerning polypeptides with modifications that increase its binding affinity for the Fab region of an antibody. Methods include using the polypeptides for isolating, detecting, purifying, measuring and quantifying Fab polypeptides. Other embodiments concern kits, compositions, and solid supports containing the polypeptides and for using the polypeptides for isolating, detecting, purifying, measuring and quantifying Fab polypeptide.
Abstract: This invention provides a peptide consisting of (i) the amino acid sequence LSSTQAQQSY (SEQ ID NO: 1), (ii) the amino acid sequence LSSTQAQQSW (SEQ ID NO: 6), or (iii) the amino acid sequence LSSTQAQQSF (SEQ ID NO: 7).
Abstract: One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP polypeptides and methods for making the same. In particular, the present invention provides methods and compositions for in vitro and in vivo addition, deletion, or modification of sugar residues to produce SAP polypeptides, such as a human SAP polypeptide, having a desired glycosylation pattern.
Abstract: The present disclosure provides opsins, including variant opsins with increased activity and/or increased trafficking to the plasma membrane. The opsins are useful in therapeutic and screening applications, which are also provided.
Type:
Application
Filed:
October 31, 2017
Publication date:
February 15, 2018
Inventors:
Karl Deisseroth, Feng Zhang, Viviana Gradinaru
Abstract: The present invention relates to hemojuvelin-IgG Fc domain fusion proteins, variants, derivatives, fragments and peptide mimetics derived therefrom and methods of using these fusion proteins for the regulation of iron homeostasis and the treatment of diseases related to iron homeostasis.
Type:
Application
Filed:
July 17, 2017
Publication date:
February 15, 2018
Inventors:
Herbert Y. Lin, Jodie L. Babitt, Tracey Menhall, Patrick Gearing
Abstract: Described herein are FGF-23 epitope peptides, methods of producing antibodies in laying hens by injecting the peptides, and methods of improving resistance to eggshell breakage and/or increasing eggshell strength by administering an FGF-23 epitope peptide to a laying hen.
Type:
Application
Filed:
August 11, 2017
Publication date:
February 15, 2018
Inventors:
Mark Eric Cook, Zhouzheng Ren, Alexis Jo Piepenburg, Daniel Butz
Abstract: The present invention relates to fusion proteins comprising a binding protein and an IL-15 polypeptide as well as uses thereof, pharmaceutical compositions comprising such fusion proteins and a method for producing such fusion proteins.
Type:
Application
Filed:
March 7, 2016
Publication date:
February 15, 2018
Inventors:
Jung GUNDRAM, Helmut SALIH, Cornelia LINDNER, Berit LOCHMANN
Abstract: The present invention provides for nucleic acids improved for the expression of interleukin-15 (IL-15) in mammalian cells. The invention further provides for methods of expressing IL-15 in mammalian cells by transfecting the cell with a nucleic acid sequence encoding an improved IL-15 sequence. The present invention further provides expression vectors, and IL-15 and IL-15 receptor alpha combinations (nucleic acid and protein) that increase IL-15 stability and potency in vitro and in vivo. The present methods are useful for the increased bioavailability and biological effects of IL-15 after DNA, RNA or protein administration in a subject (e.g. a mammal, a human).
Abstract: The present invention relates to Orexin-B polypeptides and uses thereof, in particular for the treatment of cancer. In particular, the polypeptide of the present invention comprises the amino acid sequence ranging from the amino acid residue at position 6 to the amino acid residue at position 28 in SEQ ID NO:2 wherein at least one amino acid residue position 6, 7, 8, 9, 10, 12, 13, 14, 19, 21 or 23 is substituted and the amino acid residues at position 11; 15; 16; 17; 18; 20; 22; 24; 25; 26; 27; and 28 are not deleted or substituted.
Abstract: The invention relates to novel stable and protracted GLP-1/glucagon receptor co-agonists, to the use of said peptides in therapy, to methods of treatment comprising administration of said peptides to patients, and to the use of said peptides in the manufacture of medicaments.
Type:
Application
Filed:
August 15, 2017
Publication date:
February 15, 2018
Inventors:
Ulrich Sensfuss, Thomas Kruse, Jesper F. Lau
Abstract: The use of two tandem microfiltration (MF) steps in a process for making recombinant insulin is described. The two MF steps in a single downstream purification unit operation reduce both soluble and insoluble impurities and exchange the insulin product into a suitable buffer for downstream purification.
Type:
Application
Filed:
March 3, 2016
Publication date:
February 15, 2018
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Sean S. Gant, Michael J. Iammarino, Kristi Kerchner, Michael A. Rauscher, David J. Roush, Christopher H. Smith, Martin Chandler, Matthew Petroff
Abstract: Methods and compositions are described for management of the pharmacokinetic properties of active agents, e.g., therapeutic moieties, by conjugating, fusing, or non-direct linkage of the active agent to one or more wild-type or modified heparin-binding peptides (HB). Compounds may be administered to tissues including skin. Contemplated uses include treatment of disease, allergen immunotherapy, and immunization. Other aspects relate to compositions, methods and kits comprising heparin-binding peptides (HB) fused or conjugated to the therapeutic agents.
Type:
Application
Filed:
October 3, 2017
Publication date:
February 15, 2018
Inventors:
Richard T. LEE, Parth PATWARI, James PANCOAST
Abstract: The present invention provides a method of bioluminescence-driven optogenetic control of excitable cells. The excitable cell expresses a light-gated ion channel, and a luminescent protein can be expressed either in the excitable cell or in another cell proximal to the excitable cell. The methods of the invention can be used to desynchronize local activity of excitable cells in a mammalian tissue. The methods of the invention can be used to treat a disease or condition in a mammal, the disease or condition being related to bursting. The disease or condition can be Parkinson's disease, epilepsy, a sleep disorder, or a sensory-related disease or condition (e.g., attention deficit disorder or pain). The invention also provides a conjugate of containing a voltage-gated ion channel and a luminescent protein.
Type:
Application
Filed:
January 22, 2016
Publication date:
February 15, 2018
Inventors:
Christopher I. MOORE, Ute HOCHGESCHWENDER, Diane LIPSCOMBE
Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or
Type:
Application
Filed:
November 9, 2015
Publication date:
February 15, 2018
Applicants:
Rinat Neuroscience Corp., Cellectis
Inventors:
Arvind RAJPAL, Shobha Chowdary POTLURI, Laurent POIROT, Alexandre JUILLERAT, Thomas Charles PERTEL, Donna Marie STONE, Barbra Johnson SASU
Abstract: The objective of the present invention is to provide a peptide of which both of binding forces to a Fc region and a Fab region are superior. In addition, the objective of the present invention is to provide a DNA which encodes the peptide, a vector which contains the DNA, and a transformant which is transformed by the vector. The problem can be solved by providing the peptide having the specific sequence.
Abstract: Provided is an Fc fusion high affinity IgE receptor ?-chain having excellent stability at low pH. An Fc fusion protein comprising: (i) a high affinity IgE receptor ?-chain; and (ii) an Fc region of IgG1, wherein a linker fragment region between the (i) and the (ii) is the amino acid sequence shown in SEQ ID NO: 2.
Abstract: A non-toxic anti-angiogenesis protein that inhibits tumor growth and exhibits in vitro activity in induction of angiogenic endothelial cell apoptosis without targeting VEGF/VEGFR or any other RTK pathways is described. The protein targets integrins ?v?3, at a groove in the ?A domain of ?3 formed by ?2 helix, B-C loop, and ?2-?3 loop.
Type:
Application
Filed:
March 4, 2016
Publication date:
February 15, 2018
Inventors:
Zhi-Ren Liu, Chakra Ravi Turaga, Jenny Yang
Abstract: The present disclosure relates to immunomodulatory fusion proteins containing an extracellular binding domain and an intracellular signaling domain, wherein binding of a target can generate a modulatory signal in a host cell, such as a T cell. The present disclosure also relates to uses of immune cells expressing such immunomodulatory fusion proteins to treat certain diseases, such as cancer or infectious disease.
Type:
Application
Filed:
March 4, 2016
Publication date:
February 15, 2018
Inventors:
Shannon K. Oda, Philip D. Greenberg, Thomas M. Schmitt
Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.
Type:
Application
Filed:
May 9, 2017
Publication date:
February 15, 2018
Inventors:
Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Daniel Fleischanderl, Gregor Bramberger
Abstract: The present invention is directed to a monoclonal antibody that binds specifically to a Staphylococcus aureus glucosaminidase and inhibits in vivo growth of S. aureus. Also disclosed are monoclonal antibody binding portions, recombinant or hybridoma cell lines, pharmaceutical compositions containing the monoclonal antibody or binding portions thereof, and methods of treating S. aureus infection and osteomyelitis, and methods for introducing an orthopedic implant into a patient using the monoclonal antibody, binding portion, or pharmaceutical composition of the present invention.
Type:
Application
Filed:
August 21, 2017
Publication date:
February 15, 2018
Inventors:
Edward M. SCHWARZ, Mark A. SULLIVAN, John L. DAISS
Abstract: The present invention relates to glycosylated immunoglobulin variable domains, and in particular to glycosylated immunoglobulin single variable domains (the latter also being referred to herein by means of the abbreviation “ISF” or “ISVD”). The present invention relates to glycosylated immunoglobulin heavy-chain variable domains (also referred to herein as “VH domains”), and in particular to glycosylated immunoglobulin heavy-chain ISVD's. The invention in particular relates to immunoglobulin (single) variable domains that are glycosylated in such a way that the binding of said immunoglobulin (single) variable domains by so-called “pre-existing antibodies” is prevented and/or reduced (i.e. partially or essentially completely) compared to the same immunoglobulin (single) variable domain without the glycosylation of the invention being present.
Abstract: Specific binding members that bind the ED-A isoform of fibronectin for use in methods of treatment, diagnosis, detection and/or imaging of inflammatory bowel disease (IBD), and/or for use in delivery to the IBD tissue of a molecule conjugated to the specific binding member. The specific binding member may, for example, be conjugated to an immunosupressive or anti-inflammatory molecule, such as interleukin-10.
Type:
Application
Filed:
June 1, 2017
Publication date:
February 15, 2018
Inventors:
Giovanni Neri, Kathrin Schwager, Melanie C. Ruzek, Denise M. O'hara, Jianqing Chen
Abstract: The invention provides for a fusion protein comprising a 3E10 Fv joined to a Hsp-70, Hsp-27, Hsp-90 or GRP-78 or portion thereof, and optionally, the 3E10 Fv comprising an amino acid sequence AGIH at its amino terminus.
Type:
Application
Filed:
July 14, 2017
Publication date:
February 15, 2018
Inventors:
Richard H. Weisbart, Robert N. Nishimura, James E. Hansen
Abstract: The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same.
Type:
Application
Filed:
August 25, 2017
Publication date:
February 15, 2018
Applicant:
Novartis AG
Inventors:
John TRAUGER, Andrei Igorevich VOZNESENSKY
Abstract: Apparatuses, compositions and methods for removing cells which interfere with regenerative processes. The apparatuses, compositions and methods selectively kill partially functional and/or non-functional cells versus functional cells while protecting functional proliferative cells to the extent that, upon removal of the killed cells by disintegration or scavenging, functional cells replace the partially- or non-functional cells.
Abstract: A modified IgG antibody binds and neutralizes TGF?1 selectively and with high affinity and avidity. The modified IgG antibody comprises four polypeptide chains and may comprise modifications to the elbow regions of the polypeptide chains. The modified IgG antibody may comprise the same VH and VL domains or CDR regions as metelimumab. The modified IgG antibody is useful in therapeutic and diagnostic applications.
Abstract: The present invention relates to a use of MIP-1? inhibitor for promoting angiogenesis in diabetes mellitus patients so as to improve tissue ischemia in damaged area and to prevent diabetic vasculopathy.